FOLLOWING:0FOLLOWERS:0
damon987

Author Popular Blog

Human Microbiome-based Products Market growing at an annualized rate of over 40%
2021-04-21 05:12 BY damon987
Over the years, extensive R&D efforts have enabled microbiome-based therapy / diagnostic developers to make significant strides, in terms of progressing p
0 8
Human Microbiome-based Products Market is projected to be worth USD 4 Billion by 2030
2021-04-21 04:57 BY damon987
Over the years, extensive R&D efforts have established the basis for a wide range of microbiome-based therapeutic and diagnostic products, which may cause
0 30
“Oligonucleotide Synthesis, Modification and Purification Services Market”
2021-04-14 00:04 BY damon987
To order this 300+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/oligonucleotide-synthesis/304.htmlKey Inclusions§ A deta
0 10
More than 80 companies currently claim to offer manufacturing related services, at different scales of operations.
2021-04-13 23:40 BY damon987
Several big pharma companies are known to outsource more than half of their clinical-stage oligonucleotide manufacturing operations. Anticipating a sharp rise
0 10
Modification and purification services market is projected to grow at an annualized rate of ~10%,
2021-04-13 23:36 BY damon987
Roots Analysis has done a detailed study on “Oligonucleotide Synthesis, Modification and Purification Services Market: Focus on Research, Diagnostic and Ther
0 27
The oligonucleotide synthesis market is estimated to be worth USD 5.8 billion in 2030,
2021-04-13 23:31 BY damon987
The applications of oligonucleotides are vast, even beyond the life science / pharma sector; however, owing to complexities associated with the synthesis and
0 11
“HPAPI and Cytotoxic Drugs Manufacturing Market (3rd Edition), 2020-2030”
2021-04-13 23:26 BY damon987
To order this detailed 300+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.ht
0 14
Close to 120 companies across the globe claim to possess the required expertise (Roots Analysis)
2021-04-13 23:21 BY damon987
Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies general
0 6
The HPAPI and cytotoxic drugs contract manufacturing market is projected to reach USD 25 billion by 2030
2021-04-13 23:15 BY damon987
Roots Analysis has done a detailed study on “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030”, covering key aspects of the industry’s evolution
0 8
Growing at an annualized rate of 12%, the HPAPI and cytotoxic drugs contract manufacturing (Roots Analysis)
2021-04-13 23:11 BY damon987
Manufacturing highly potent drug products is technically and financially demanding; as a result, drug manufacturers are becoming increasingly reliant on contr
0 12
“Cell Therapy Manufacturing Market (3rd Edition), 2019-2030” (Roots Analysis)
2021-04-07 03:14 BY damon987
To order this 550+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.htmlKey Inclusions§ A d
0 20
More than 100 industry players and over 60 non-industry players currently claim to manufacture (Roots Analysis)
2021-04-07 03:10 BY damon987
Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract serv
0 32
Cell therapy manufacturing market is projected to grow at an annualized rate of >16.5%, (till 2030)
2021-04-07 01:07 BY damon987
Roots Analysis has done a detailed study on Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030”, covering various important aspects of the industry a
0 15
The cell therapy manufacturing market is estimated to reach close to USD 11 Billion by 2030 (Roots Analysis)
2021-04-07 01:03 BY damon987
Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertis
0 16
Growing at an annualized rate of over 16.5% (claims Roots Analysis)
2021-04-07 00:58 BY damon987
The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the techni
0 48